How Does Multiple Myeloma Kill You: What It Means, What to Expect and When to See a Specialist

A retired schoolteacher once described her diagnosis this way: the word cancer arrived, but nothing hurt. She had back pain she blamed on gardening, a tiredness she blamed on age, and a blood test that came back with a protein her doctor had never seen in her chart before. Nobody, at that first appointment, said anything about dying. She went home and typed the question into a search bar anyway.

Almost everyone does. The results are a mix of survival curves, forum posts about someone’s father, and clinical summaries that never quite answer the thing people actually want to know: what does this disease do, physically, when it wins?

The honest answer is more specific, and in some ways more manageable, than the fear suggests. Myeloma has a small number of ways to harm a body, each with a mechanism that can be measured, watched and often interrupted. Understanding them is not morbid. It is how people and families make good decisions.

What actually happens in the body with multiple myeloma?

Plasma cells are the immune system’s antibody factories. Each one is supposed to make a single, specific antibody in response to a specific germ, then quiet down. Myeloma begins when one plasma cell acquires genetic damage and refuses to quiet down. It copies itself, and every copy churns out the same antibody, or a fragment of it, in enormous quantity. Doctors call this the M protein or paraprotein, and the fragments are called light chains.

That single fact drives nearly everything that follows. The clone lives in the bone marrow, the soft tissue inside bones where red cells, white cells and platelets are made. As it expands, it takes up space and sends chemical signals that reshape its neighborhood. Bone-dissolving cells switch on. Bone-building cells switch off. Healthy blood production slows. The protein spills into the blood and urine.

Clinicians summarize the results with the acronym CRAB, described by the Mayo Clinic and the NHS: elevated Calcium, Renal (kidney) damage, Anemia, and Bone lesions. Those four letters are also, in a sense, the map of how the disease can shorten a life.

One more distinction matters. Some people have a precursor condition in which the abnormal protein is present but no organ damage has occurred. The NHS and Mayo Clinic note that this smoldering form is monitored rather than treated, and many people carrying it never develop active disease. The rest of this article is about active myeloma, the kind that causes harm.

How does multiple myeloma kill you? The four main pathways

It helps to think of myeloma less as a tumor that grows in one place and more as a factory that poisons its own building. The malignant cells seldom form a mass large enough to press on a vital organ the way a lung or brain tumor might. Instead, they kill indirectly through four connected pathways.

The first is infection. A marrow full of useless plasma cells produces too few useful antibodies and, over time, too few neutrophils, the white cells that swarm bacteria. Pneumonia and bloodstream infections become both more likely and more dangerous.

The second is kidney failure. Light chains are small enough to pass through the kidney’s filters, where they can clog and scar the tubules. High calcium and dehydration add to the strain.

The third is the skeleton itself. Dissolving bone releases calcium into the blood, which at high levels disturbs the heart, the brain and the kidneys. Weakened vertebrae can collapse and compress the spinal cord.

The fourth is marrow failure: anemia severe enough to strain the heart, and low platelets that raise bleeding risk.

These pathways reinforce each other. An infection dehydrates a person, which tips the kidneys, which raises calcium, which causes confusion and falls, which fractures a weakened hip. When clinicians talk about complications as the cause of death, this cascade is what they mean. The Cleveland Clinic describes infection and kidney problems as among the most serious of these complications, and much of modern myeloma care is aimed at breaking the chain early.

Why infections are the most dangerous complication

A healthy immune system carries an enormous library of antibodies, each shaped to one invader. In myeloma the library is quietly replaced by a warehouse holding millions of copies of one book. Blood tests show the effect as a drop in the normal immunoglobulins even while total protein looks high, a pattern sometimes called immunoparesis.

That is only the first layer. As the disease progresses, neutrophil counts often fall because the marrow is crowded. Many treatments, by design, further suppress the immune system while they suppress the cancer. Kidney damage impairs immune function too. The result is that an ordinary chest infection, which a peer without myeloma would shake off in a week, can progress to pneumonia and then to sepsis in a matter of days.

The signs are often blunted. Fever may be mild or absent. What families tend to notice instead is a sudden change: confusion, breathlessness, a person who was walking on Monday and cannot get out of bed on Wednesday. The NHS and Cleveland Clinic both list frequent or persistent infections among the warning features of myeloma, and clinicians treat any fever in a person with active myeloma as urgent.

Why does this matter for the question at hand? Because infection is the complication most likely to end a life relatively quickly, and also the one most responsive to prompt action. Antibiotics started in the first hours of a serious infection change outcomes. That is the reason care teams give patients a card or a phone number and tell them, plainly, to call at the first sign of a temperature or a shiver.

How myeloma damages the kidneys

Each kidney contains roughly a million filtering units. Blood is pushed through a fine sieve, and the fluid that passes through travels down a series of tiny tubes where the body reclaims what it wants and discards the rest. Light chains slip through the sieve easily. In normal amounts the tubes handle them. In myeloma, the sheer volume overwhelms the reclaiming cells, and the chains combine with another protein to form solid casts that block the tubes like sediment in a drainpipe.

This is the classic myeloma kidney, and it is why kidney function is checked at diagnosis and at every follow-up. It is not the only route to damage. High blood calcium constricts the kidney’s blood vessels and causes heavy urination, which dehydrates a person and concentrates the light chains further. Certain common over-the-counter pain relievers, which people naturally reach for when their bones ache, reduce blood flow inside the kidney; clinicians usually advise avoiding them, and any decision about pain medication belongs with the prescribing team.

When kidney function fails, waste products build up. A person becomes nauseated, itchy, drowsy and short of breath as fluid accumulates. Potassium can rise to levels that stop the heart. In the most advanced situations this is a recognized way that myeloma leads to death, and it is one reason the Mayo Clinic lists kidney problems among the disease’s main complications.

The hopeful side is that light-chain kidney injury is often reversible if the protein load falls quickly. Rapid treatment to shut down the plasma cell clone, along with fluids and correction of calcium, can restore function in many people. Timing is the whole game.

What does myeloma do to your bones and calcium levels?

Bone is not inert. Two cell types constantly remodel it: osteoclasts dissolve old bone and osteoblasts lay down new bone. Myeloma cells release signals that turbocharge the dissolvers and paralyze the builders. The result, visible on imaging, is a scattering of punched-out holes called lytic lesions, most often in the spine, ribs, pelvis and skull.

Bone pain is the most common symptom that brings people to a doctor, according to the Mayo Clinic and the NHS. It tends to be a deep ache, worse with movement, often in the lower back or ribs. A vertebra hollowed by disease can collapse under ordinary body weight, causing sudden severe pain and, in some cases, pressing on the spinal cord. Spinal cord compression is a true emergency: new weakness or numbness in the legs, or loss of bladder or bowel control, needs same-day hospital assessment because the window to preserve function is short.

The dissolved bone has to go somewhere, and it goes into the blood as calcium. Mild elevations cause thirst, constipation and fatigue. Higher levels bring nausea, confusion, drowsiness and abnormal heart rhythms. Untreated severe hypercalcemia can cause coma and death on its own, and it accelerates the kidney injury described above.

Modern imaging has changed how early this damage is caught. Whole-body low-dose CT and MRI find lesions long before a plain X-ray would, and PET scanning can distinguish active disease from old scarring. Skeletal damage remains the complication that most affects daily quality of life, yet fractures and high calcium are, in themselves, rarely the final cause of death in someone receiving care.

Anemia, bleeding and thick blood: when the marrow runs out of room

Picture the marrow as a workshop with fixed floor space. As the plasma cell clone expands, red cell production is the first casualty. Anemia develops slowly enough that many people adapt without realizing it; they climb stairs more slowly, nap in the afternoon, feel their heart pounding after mild effort. MedlinePlus lists fatigue and weakness among the earliest and most common symptoms of the disease for exactly this reason.

Severe anemia strains the heart, which has to pump harder to deliver the same oxygen. In an older person with existing heart disease this can precipitate heart failure or angina. Kidney damage worsens the anemia further because the kidneys make the hormone that tells the marrow to produce red cells.

Platelets fall later. When they do, bruising appears without injury, gums bleed, and small cuts take a long time to stop. Bleeding into the brain or gut is uncommon but possible in advanced, treatment-resistant disease.

There is a less familiar problem too. Some forms of the abnormal protein thicken the blood itself, a state called hyperviscosity. Blood moves sluggishly through the smallest vessels, producing blurred vision, headaches, nosebleeds and confusion. It is uncommon in myeloma compared with related plasma cell disorders, but when it occurs it can be relieved quickly by filtering the protein out of the blood.

None of these marrow effects tends to kill in isolation. Their significance is cumulative: a person who is anemic, bleeding-prone and short of white cells is one bad infection away from a crisis, and that is how the story usually turns.

Is dying from multiple myeloma a painful death?

People ask this question quietly, often on behalf of someone else, and they deserve a straight answer rather than reassurance. Myeloma can be a painful disease to live with. Bone lesions and fractures cause real, sometimes severe pain, and the Mayo Clinic lists bone pain as a hallmark symptom. That is different from saying that dying of myeloma is necessarily painful.

Pain from bone disease is well understood and responds to a layered approach: medicines chosen and adjusted by the treating team, radiation to a single painful spot, procedures that stabilize a collapsed vertebra, and physical support such as braces. Palliative care specialists, who can be involved from diagnosis rather than only at the end, focus precisely on this problem. Well-controlled pain is a realistic expectation, not a lucky exception.

The final days themselves more often look like withdrawal than agony. As infection, kidney failure or marrow failure advance, people become profoundly tired, sleep for longer stretches, eat and drink less, and drift in and out of awareness. Breathlessness from fluid or pneumonia is common and is treatable with medicines and positioning. Confusion from high calcium or kidney failure can be distressing for families to witness but is usually not experienced as suffering by the person, who is often only partly aware.

Where suffering does occur, it is most often because symptoms were not anticipated or help was not requested early enough. Hospice and palliative teams exist to prevent exactly that. Asking about them is not giving up; it is planning, and the evidence from mainstream cancer care consistently shows that people who receive good symptom control live more comfortably in the time they have.

What are the signs of myeloma getting worse?

Myeloma is monitored more precisely than most cancers because its signature protein can be measured in a tube of blood. A rising paraprotein or a climbing ratio of light chains is often the first sign of relapse, sometimes months before a person feels anything. That lead time is one of the quiet triumphs of laboratory technology, and it is why follow-up appointments continue even when someone feels well.

The physical signs tend to follow the same four pathways described earlier. Watch for:

• New or worsening bone pain, particularly in the back or ribs, or pain that wakes a person at night
• Unexplained fatigue, breathlessness on mild exertion, or paleness suggesting the red count is falling
• Infections that come back, linger, or need hospital treatment
• Increased thirst, frequent urination, constipation or new confusion, which together point to rising calcium
• Swollen ankles, reduced urine output or nausea, which can signal declining kidney function
• Easy bruising or bleeding from gums and nose

Blood tests add the numbers behind those signs: hemoglobin, creatinine, calcium and the protein markers. Imaging is repeated if new pain appears. Some centers now also use highly sensitive tests that can detect one myeloma cell among a million normal marrow cells, a measure called minimal residual disease, which helps predict how long a remission is likely to last.

The pattern that matters most is the pace. Myeloma that returns slowly, after years, and responds again to treatment behaves very differently from disease that comes back within months and shrugs off successive therapies. Clinicians use the words relapsed and refractory to distinguish the two, and the second word carries more weight than the first.

What are the final stages of multiple myeloma?

The clinical staging systems used at diagnosis, which sort people into stages one to three based on blood markers and genetics, describe how much disease is present and how aggressively it is likely to behave. They are not a timeline. Someone can be stage three at diagnosis and live for many years. The phrase final stages, as families use it, means something different: disease that no longer responds to available treatment and a body that is running out of reserve.

That period has recognizable features. Remissions become shorter with each line of therapy. Blood counts recover less fully between treatments. Infections come more often. Weight falls, appetite fades, and the person spends more of the day resting. Kidney function may decline in a way that no longer reverses. At some point, the treating team and the patient reach a conversation about whether further anti-myeloma therapy is likely to add time that is worth the side effects, or whether the focus should shift entirely to comfort.

The last weeks typically involve a combination of the pathways already described: a serious infection, worsening kidney failure, or simply a marrow that cannot keep pace. Sleepiness increases. Eating stops being important. Breathing may change. Most people die in a hospital, hospice or at home with palliative support rather than in an emergency.

What families most often say they wish they had known is that this phase is usually visible some time in advance. Doctors can rarely predict a date, but they can usually tell when the direction has changed, and asking directly gives everyone the chance to make plans, say things, and choose where care happens.

How long can you live with multiple myeloma?

Survival statistics are averages drawn from large populations, and they lag behind current treatment by several years because the people counted were diagnosed in the past. With that caveat, the figures below come from the National Cancer Institute’s SEER program, which tracks cancer outcomes across the United States.

Measure	What SEER reports	What it means in plain terms
Five-year relative survival, all stages combined	About 6 in 10	Roughly six of every ten people diagnosed are alive five years later, compared with peers of the same age without the disease
Localized disease (a single plasma cell tumor)	Roughly 8 in 10	A small minority of cases; often treated with radiation to the one site
Distant disease (true multiple myeloma)	Roughly 55 to 60 percent	The majority of cases fall here
Median age at diagnosis	69 years	Half of people are older than this at diagnosis, half younger

Two things stand out. The first is direction of travel. SEER data show five-year survival for myeloma has roughly doubled over the past few decades, a change driven by new classes of treatment rather than earlier detection. The second is spread. An average of six in ten hides a wide range, from people who relapse within a year to people who are alive and active fifteen years on.

Individual prognosis depends on the stage at diagnosis, specific genetic changes inside the myeloma cells, kidney function, how well the disease responds to first treatment, and general fitness. A hematologist looking at one person’s results can offer a far more meaningful estimate than any table, and it is reasonable to ask for that conversation.

What is the prognosis for multiple myeloma after age 75?

Myeloma is largely a disease of later life. SEER data place the median age at diagnosis at 69, and a substantial share of new cases occur in people over 75. The question families ask about an older parent is therefore the question most families are asking.

Age by itself is a blunt instrument. Two 78-year-olds can have entirely different prospects: one walking a mile each morning with good kidneys and a sound heart, the other managing diabetes, heart failure and a recent fall. Hematologists increasingly use formal frailty assessments, which score physical function, other illnesses and daily independence, to guide how intensive treatment should be. A fit older person may tolerate approaches once reserved for the young; a frail one benefits from gentler regimens that aim to control disease with fewer side effects.

Population statistics do show shorter survival in the oldest groups. Part of that reflects the biology of the disease and the reality that other health conditions compete for the same years. Part reflects a history of under-treatment, since older people were often excluded from the studies that established newer therapies. That gap is narrowing, and outcomes for people over 75 have improved along with everyone else’s.

What matters most in this age group is arguably not the survival curve but the balance between disease control and daily life. Reducing bone pain, keeping the kidneys working, avoiding hospital admissions for infection and preserving independence are outcomes that can be achieved for most older people even when a cure is not on the table. The best prognosis conversation for someone over 75 starts with asking what they want their next year to look like.

How do modern treatments change the way myeloma behaves?

The reason survival has improved so markedly is that clinicians now have several ways to attack plasma cells that work through different mechanisms and can be combined. None of them cures the disease in the ordinary sense; what they do is push it back, often to undetectable levels, and hold it there.

One class blocks the cell’s waste-disposal machinery. Plasma cells make vast quantities of protein and depend on constantly clearing misfolded copies; jam that system and the cell dies under its own clutter. Another class alters signaling inside the cell and simultaneously wakes up the immune system around it. A third uses laboratory-made antibodies that latch onto a marker on the myeloma cell surface and flag it for destruction, or physically link a patient’s own T cells to the cancer cell. Newer approaches go further, engineering a person’s immune cells outside the body to recognize myeloma before returning them.

For people fit enough, high-intensity treatment followed by an infusion of their own previously collected stem cells remains a standard option that can produce long remissions. Bone-protecting medicines reduce fracture risk. Radiation quiets individual painful lesions.

Typical timelines matter for expectations. Initial treatment usually runs for several months, with the paraprotein falling within the first weeks. Many people then continue a lower-intensity maintenance approach for years. When the disease returns, a different combination is chosen, and the cycle repeats. Every one of these decisions, including which class to use and for how long, rests with the prescribing hematologist, who weighs the individual disease, kidney function, other conditions and the person’s own priorities.

When to see a specialist, and which signs cannot wait

Myeloma is treated by hematologists, and anyone with a confirmed diagnosis should be under the care of one, ideally at a center that treats the condition regularly. Before diagnosis, the reasons to ask a primary care doctor for blood tests include persistent bone pain without an obvious cause, unexplained fatigue, repeated infections, or an abnormal protein or calcium result on routine testing. The Cleveland Clinic and Mayo Clinic both describe this cluster as the typical route to diagnosis.

For someone already living with myeloma, certain symptoms need same-day contact with the care team or an emergency department rather than a wait for the next appointment. A temperature or shivering episode can signal an infection that will move fast. New weakness, numbness or tingling in the legs, or any change in bladder or bowel control, may mean spinal cord compression and needs immediate assessment. Sudden confusion, extreme thirst or drowsiness can indicate dangerously high calcium. A sharp fall in urine output, swelling of the legs or persistent vomiting can point to kidney injury. Severe new bone pain after even minor movement may be a fracture. Unusual bleeding, black stools or a bad headache with blurred vision also warrant urgent review.

Beyond emergencies, the specialist relationship works best when it is two-way. Bring a written list of new symptoms. Ask what the latest protein and kidney numbers show and which direction they are moving. Request a palliative care referral early if pain, fatigue or anxiety are wearing you down; it is a service for living well, not only for the end. If the conversation about prognosis has not happened and you want it to, say so plainly. Clinicians are trained to have that conversation, and most would rather have it than leave a family guessing.

What matters most: an editor's view grounded in the evidence

Having read the survival tables and the mechanism papers, here is the opinion this article has been building toward. The single most useful thing a person with myeloma or their family can do is to understand that this disease kills through a short list of complications, and that each of those complications announces itself.

Infection announces itself with a fever or a sudden slump. Kidney trouble announces itself in a blood test taken on schedule. Bone collapse announces itself with pain that should never be dismissed as ordinary backache. High calcium announces itself with thirst and confusion. People who know these signals, and who act on them within hours rather than days, spend less time in hospital and more time in their own lives. That is not a slogan; it follows directly from the way the disease works.

The second thing that matters is the quality of the relationship with the treating team. Myeloma is a long-haul condition managed over years, through remissions and relapses, and the people who do best tend to be those who ask direct questions, keep appointments even when they feel well, and involve palliative and supportive care early rather than late.

The third is perspective. A diagnosis made in this decade carries a very different outlook from one made when today’s older patients were young. The schoolteacher from the opening paragraph is a composite, but her trajectory is typical: years of good life after a frightening search result. The statistics she found were true and also incomplete. The complete answer includes the mechanisms, the warning signs, the treatments that interrupt them, and the care that keeps the end, when it comes, as gentle as medicine can make it.

Frequently asked questions

Is dying from multiple myeloma a painful death?

Not necessarily, and usually not when symptoms are well managed. Myeloma can cause significant bone pain during life, but that pain responds to medicines, targeted radiation and supportive procedures. In the final weeks, people more often experience deep tiredness, increased sleep and reduced awareness than severe pain. Palliative and hospice teams specialize in controlling pain and breathlessness, and involving them early makes a comfortable death far more likely.

What are the final stages of multiple myeloma?

The final stage is disease that no longer responds to available treatment, marked by shorter remissions, falling blood counts, frequent infections, weight loss and declining kidney function. People sleep more, eat less and lose energy for daily tasks. Death usually follows an infection, kidney failure or marrow failure. Clinicians can typically recognize when this phase has begun, even if they cannot predict a date, which allows time for planning and comfort-focused care.

What are the signs of myeloma getting worse?

Rising paraprotein or light chain levels on blood tests are usually the earliest sign. Physical signs include new or worsening bone pain, growing fatigue or breathlessness, infections that recur or linger, increased thirst and confusion from high calcium, swollen ankles or reduced urine from kidney decline, and easy bruising. Disease that relapses quickly and resists successive treatments is more concerning than disease that returns slowly after years.

What is the prognosis for multiple myeloma after age 75?

It varies widely and depends more on overall fitness than on age alone. Population data show shorter average survival in the oldest groups, partly because other illnesses compete for the same years and partly because older people were historically under-treated. Hematologists now use frailty assessments to match treatment intensity to the individual, and outcomes for people over 75 have improved. Controlling pain, protecting kidneys and preserving independence are realistic goals.

What is the most common cause of death in multiple myeloma?

Infection is the complication most often responsible, followed by kidney failure. Myeloma crowds out the normal antibodies and white cells that fight germs, and treatment can suppress immunity further, so pneumonia and bloodstream infections progress quickly. Kidney failure results from abnormal light chains clogging the filtering tubules, often worsened by high calcium and dehydration. These pathways frequently combine, with one problem triggering the next.

Can multiple myeloma be cured?

It is generally considered treatable but not curable with current approaches. Treatment can drive the disease to undetectable levels and hold it there for years, and some people remain in remission for a decade or more. The disease usually returns eventually, and a different combination of treatments is then used. Research into immune-based therapies continues to lengthen remissions, and clinicians increasingly describe myeloma as a long-term condition managed over time.

How quickly does multiple myeloma progress?

The pace differs greatly between people. Some have a smoldering form that causes no organ damage for years and is only monitored. Active disease at diagnosis usually needs treatment within weeks, particularly if kidneys or bones are involved. After treatment, remissions can last from months to many years. Genetic features of the myeloma cells, kidney function at diagnosis and response to first treatment all influence how fast the disease moves.

Does multiple myeloma affect the brain?

Rarely through direct spread, but often indirectly. High blood calcium from bone breakdown causes confusion, drowsiness and, if severe, coma. Kidney failure leads to a buildup of waste products that clouds thinking. Thickened blood from excess protein can cause headaches and blurred vision. Infections in someone with a weakened immune system also frequently present as sudden confusion rather than fever. Any new confusion in a person with myeloma should be assessed promptly.

What is the difference between relapsed and refractory myeloma?

Relapsed myeloma is disease that returns after a period of response to treatment, which is expected at some point for most people and is usually treatable again with a different approach. Refractory myeloma is disease that does not respond to a treatment or progresses during it. Disease that is refractory to several classes of therapy is harder to control and carries a shorter outlook, which is why this distinction matters in prognosis discussions.

When should someone with myeloma go to the emergency department?

Immediately for any fever or shivering, because infection can become life-threatening within hours. Same-day assessment is also needed for new leg weakness, numbness, or loss of bladder or bowel control, which may indicate spinal cord compression; for sudden confusion, severe thirst or drowsiness suggesting high calcium; for a sharp fall in urine output or persistent vomiting pointing to kidney injury; and for severe new bone pain or unusual bleeding.

References

• NHS: Multiple myeloma
• Cleveland Clinic: Multiple Myeloma
• MedlinePlus: Multiple Myeloma

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.